This property candidates irisin as a potential therapeutic target in metabolic diseases, including metabolic syndrome, T2DM, and nonalcoholic fatty liver disease (NAFLD), in which IR plays a major pathogenic role [143]. This evidence concerns the gene FNDC5 and metabolic disease.